Adaptive Ketone Threshold Hypothesis

Core proposition: The metabolic benefit of alternate‑day fasting (ADF) emerges not from a universal ketone level but from each individual’s ability to keep fasting β‑hydroxybutyrate (BHB) within a personalized window that reflects their intrinsic insulin‑glucose‑ketone coupling. When BHB stays above a lower threshold (~0.3 mmol/L) yet below an upper ceiling (~1.2 mmol/L) during the fasted state, subjects show improved insulin sensitivity and glucose homeostasis independent of total weight loss; exceeding the upper ceiling predicts future type 2 diabetes risk, while falling below the lower threshold signals insufficient fat‑oxidation drive and compensatory hyperphagia.

Mechanistic rationale: Recent data show that fasting ketones track fat oxidation as insulin drops [Fasting ketones track fat oxidation and metabolic shift as insulin drops], yet elevated fasting ketones independently predict diabetes incidence [Elevated fasting ketones independently predict type 2 diabetes incidence]. This paradox can be resolved if ketogenesis and glucose uptake are regulated by distinct insulin‑sensitive pathways. Lean individuals exhibit 44 % higher basal ketone flux despite similar insulin suppression [Basal ketone flux was 44 % higher in lean individuals despite similar insulin suppression of ketogenesis], indicating that their adipose tissue retains ketogenic responsiveness even when hepatic insulin signaling blunts glucose uptake. In obese subjects, adipose insulin resistance may blunt ketogenesis, forcing reliance on glucose and producing a blunted ketone rise; conversely, some obese individuals retain hepatic insulin sensitivity that allows exaggerated ketone production, marking a maladaptive spill‑over of acetyl‑CoA into ketone bodies.

Thus, the individualized ketone window reflects the balance between adipose‑derived acetyl‑CoA availability and hepatic insulin‑mediated suppression of ketogenesis. Subjects whose adipose tissue can liberate fatty acids efficiently (high basal lipolysis) generate sufficient ketones to signal fatty‑acid oxidation without overwhelming the system; those with adipose insulin resistance fail to reach the lower ketone threshold, triggering hunger and higher ad libitum intake [Impaired flexibility correlates with higher ad libitum calorie intake]. Those whose hepatic insulin signaling is overly permissive produce excess ketones, which may inhibit oxaloacetate availability, impair gluconeogenesis, and foster glucose intolerance over time.

Testable predictions:

1. In a randomized ADF trial (≥12 weeks) measuring 24‑h respiratory exchange ratio (RER), fasting BHB, fasting insulin, and continuous glucose, participants who maintain fasting BHB between 0.3–1.2 mmol/L on fast days will show a ≥15 % improvement in Matsuda insulin sensitivity index regardless of change in body weight, whereas those whose BHB consistently falls below 0.3 mmol/L will exhibit no sensitivity gain and will increase ad libitum calories by ≥10 % on feeding days.

2. Participants whose fasting BHB exceeds 1.2 mmol/L on ≥2 fast days per week will have a significantly higher incidence of pre‑diabetic HbA1c rise (≥0.3 %) over a 6‑month follow‑up compared with those staying within the window, independent of baseline adiposity.

3. Pharmacological enhancement of adipose lipolysis (e.g., β‑agonist) in low‑BHB responders will shift their fasting BHB into the target window and restore insulin sensitivity, while hepatic insulin sensitization (e.g., low‑dose metformin) in high‑BHB responders will lower fasting BHB without compromising weight loss.

Falsifiability: If the data show that insulin sensitivity improvements correlate strictly with total caloric deficit or weight loss and that fasting BHB levels—whether low, moderate, or high—have no predictive value for metabolic outcomes beyond energy balance, the hypothesis is refuted. Conversely, demonstration of a BHB‑specific window governing metabolic flexibility independent of weight change would support the proposed mechanism.